RxION Health Review

What RxION Health charges

• NAD+: $249/mo — printed as "Select your plan: Monthly Supply — $249 / month", with no anchor figure, no promotional strike-through and no plan term. The line directly below it is the seller's own disclaimer that compounded NAD+ is not FDA-approved for the indications it is sold for

The disclaimer is under the price, not under the fold

Most sellers on this roster that address approval status at all do it in a footer, a terms document or a collapsed accordion. This one puts it in the product's own buying section, immediately below the plan selector.

The sentence names the compound, names the four categories of benefit the page has just been describing, and says the product is not approved for any of them. It then says use is at the discretion of a licensed provider.

That is a seller telling a buyer, at the moment of purchase, that the marketing claims above are not approved indications. It is rare enough on this roster to be the reason this seller is worth reading.

This site quotes the sentence rather than paraphrasing it. A characterisation of a legal category written in our words would be our claim; the seller's own words are a fact about the seller.

A price with nothing attached to it

The plan selector offers a monthly supply at a single figure with the word month attached. There is no anchor price struck through, no promotional discount, no minimum term and no annual prepayment.

Several sellers in this batch publish a lower headline figure than this one and require six or twelve months of commitment to get it. This seller publishes one number and it is the number.

That makes it directly comparable to other month-to-month figures on this roster in a way that most rows here are not, and the qualifier says so explicitly rather than leaving a reader to notice.

The page also states that supplies and step-by-step injection instructions are included with every order and that clinical support continues throughout treatment.

The clinical partner is named, and that names very little

The terms name the operating company plainly in their opening sentence. A separate telemedicine page names the clinical practice that delivers care.

Naming a clinical practice reads as a transparency win, and on this network it usually is not. The practice named here stands behind a long list of nominally independent brands, several of them on this roster.

So the disclosure is accurate and it does not distinguish this seller from its competitors, because many of them disclose the same partner. That distinction is worth drawing explicitly rather than letting a checkbox carry it.

Screened by entity and by brand against the regulator's warning-letter index, neither the operating company nor the clinical partner returns a letter.

Everything else is absent

There is no certificate of analysis anywhere on the pages read, and no third-party-testing claim to be unreachable. The seller does not raise the subject.

No dispensing pharmacy is named. No state coverage list is published. Only one of the peptides in the seller's catalogue carries a published figure on the pages read.

Those are ordinary omissions on this roster rather than distinguishing ones, and they are recorded as such.

The nonsense-path control on this host returned a clean not-found status, so the pages that returned content are pages that exist.

How we verified this

• Loaded the product page and the terms with a full browser user-agent, printing the effective URL beside the requested one on both.
• Ran a nonsense-path control on the host in the same run, which returned a not-found status.
• Joined the page's text nodes before matching any figure, so a price split across elements could not read as an absence.
• Read the figure together with the sentence directly beneath it, which is how the approval-status disclaimer was established as sitting inside the buying section rather than in a footer.
• Quoted the seller's approval-status sentence into the price qualifier verbatim rather than characterising it.
• Read the terms' opening sentence for the operating company and the telemedicine page for the clinical practice.
• Compared the named clinical practice against the other sellers on this roster that name the same one, so the disclosure is not credited as a differentiator it is not.
• Screened both the operating company and the clinical practice against the regulator's warning-letter index, with a nonsense query as a control in the same run.